SCHEMBL1055898

SCHEMBL1055898

C=CC[n+]1ccccc1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.52
NPC1 O15118 2/20 0.52
POLB P06746 2/20 0.52
RAB9A P51151 2/20 0.52
KDM4E B2RXH2 4/20 0.50
KMT2A Q03164 3/20 0.37
HDAC8 Q9BY41 1/20 0.36
ACHE P22303 2/20 0.33
LMNA P02545 2/20 0.33
MEN1 O00255 2/20 0.33
MMP14 P50281 1/20 0.33
THRB P10828 1/20 0.33
BCHE P06276 1/20 0.33
SLC19A2 O60779 1/20 0.33
USP2 O75604 1/20 0.33
CASP1 P29466 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
GAA P10253 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3479723 0.98 KDM4E (0.53) SMN1; SMN2NPC1POLBRAB9AKDM4E
Bromide SCHEMBL15546500 0.98 SMN1; SMN2 (0.55) SMN1; SMN2NPC1POLBRAB9AKDM4E
Iodide SCHEMBL3433717 0.98 SMN1; SMN2 (0.50) SMN1; SMN2NPC1POLBRAB9AKDM4E
SCHEMBL11004427 0.79 KDM4E (0.46) SMN1; SMN2NPC1POLBRAB9AKDM4E
SCHEMBL3087633 0.78 KDM4E (0.44) SMN1; SMN2NPC1POLBRAB9AKDM4E
SCHEMBL11004432 0.77 KDM4E (0.43) SMN1; SMN2NPC1POLBRAB9AKDM4E
SCHEMBL8922515 0.76 SMN1; SMN2 (0.48) SMN1; SMN2NPC1POLBRAB9AKDM4E
SCHEMBL4981749 0.75 KDM4E (0.42) SMN1; SMN2NPC1POLBRAB9AKDM4E
SCHEMBL721593 0.75 HDAC8 (0.50) SMN1; SMN2NPC1POLBRAB9AKDM4E
SCHEMBL11286540 0.75 KDM4E (0.42) SMN1; SMN2NPC1POLBRAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122051358-A Gel polymer solid electrolyte membrane, preparation method thereof and application thereof in sodium metal battery 浙江钠创新能源有限公司 2026-05-15 CN claimed
US-10357751-B2 Polymer micelles containing nanoparticles in non-aqueous solution, methods for their preparation and use FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) 2019-07-23 US claimed
US-10315178-B2 Polymer micelles containing nanoparticles in non-aqueous solution, methods for their preparation and use FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) 2019-06-11 US claimed
US-20170225141-A1 POLYMER MICELLES CONTAINING NANOPARTICLES IN NON-AQUEOUS SOLUTION, METHODS FOR THEIR PREPARATION AND USE Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2017-08-10 US claimed
US-20170225140-A1 POLYMER MICELLES CONTAINING NANOPARTICLES IN NON-AQUEOUS SOLUTION, METHODS FOR THEIR PREPARATION AND USE Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2017-08-10 US claimed
EP-2953930-B1 PROCESSES FOR PREPARING 1-ALKYL-3-ALKYL-PYRIDINIUM BROMIDE AND USES THEREOF AS ADDITIVES IN ELECTROCHEMICAL CELLS BROMINE COMPOUNDS LTD (IL) 2016-12-07 EP claimed
US-20110015245-A1 BENDAMUSTINE AMPHIPHILIC CATIONIC COMPOSITIONS SUPRATEK PHARMA INC. (CA) 2011-01-20 US claimed
CN-122051358-A Gel polymer solid electrolyte membrane, preparation method thereof and application thereof in sodium metal battery 浙江钠创新能源有限公司 2026-05-15 CN disclosed
US-20240148696-A1 LYOPHILIZED BENDAMUSTINE-CYCLODEXTRIN COMPOSITION SOFTKEMO PHARMA INC. (CA) 2024-05-09 US disclosed
WO-2024091826-A1 LYOPHILIZED BENDAMUSTINE-CYCLODEXTRIN COMPOSITION SOFTKEMO PHARMA INC. (CA) 2024-05-02 WO disclosed
US-20200368355-A1 FORMULATIONS OF BENDAMUSTINE EAGLE PHARMACEUTICALS, INC. (US) 2020-11-26 US disclosed
US-10357751-B2 Polymer micelles containing nanoparticles in non-aqueous solution, methods for their preparation and use FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) 2019-07-23 US disclosed
US-10315178-B2 Polymer micelles containing nanoparticles in non-aqueous solution, methods for their preparation and use FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) 2019-06-11 US disclosed
US-20130190372-A1 BENDAMUSTINE CYCLOPOLYSACCHARIDE COMPOSITIONS SUPRATEK PHARMA INC. (CA) 2013-07-25 US disclosed
US-8436032-B2 Bendamustine cyclopolysaccharide compositions SUPRATEK PHARMA INC. (CA) 2013-05-07 US disclosed
WO-2013042110-A1 ADDITIVES FOR HYDROGEN/ BROMINE CELLS BROMINE COMPOUNDS LTD. (IL) 2013-03-28 WO disclosed
WO-2011104625-A1 CYCLOPOLYSACCHARIDE COMPOSITIONS SUPRATEK PHARMA, INC. (CA) 2011-09-01 WO disclosed
US-20110015245-A1 BENDAMUSTINE AMPHIPHILIC CATIONIC COMPOSITIONS SUPRATEK PHARMA INC. (CA) 2011-01-20 US disclosed
US-20100216858-A1 BENDAMUSTINE CYCLOPOLYSACCHARIDE COMPOSITIONS SOFTKEMO PHARMA CORP. (CA) 2010-08-26 US disclosed
US-4272620-A Polyvinyl alcohol-styrylpyridinium photosensitive resins and method for manufacture thereof AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 1981-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200368355-A1 FORMULATIONS OF BENDAMUSTINE FOLR2, BHMT, THPO SMN1; SMN2 190/4885NPC1 958/4885POLB 1488/4885
US-20240148696-A1 LYOPHILIZED BENDAMUSTINE-CYCLODEXTRIN COMPOSITION SORD, SBK1, SBDS SMN1; SMN2 505/4885NPC1 1812/4885POLB 4574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.